Status:
COMPLETED
The Role of Bifidobacterium Intervention in Food Allergic Infants
Lead Sponsor:
Ruijin Hospital
Conditions:
Food Allergy in Infants
Eligibility:
All Genders
Up to 12 years
Phase:
NA
Brief Summary
Infant food protein allergy is the most common allergic disease in children, which can lead to infantile-specific dermatitis, intestinal inflammation, and so on. Dietary avoidance is a common strategy...
Eligibility Criteria
Inclusion
- 0 -12 months infant
- Infants that are allergic (confirmed by an allergist) to at least one of the main food allergens (cow's milk, egg, soy or wheat) and is following an elimination diet to at least one of these allergens.
Exclusion
- Patients had used probiotics within 1 month prior to the study
- Allergy or intolerance to probiotics or their excipient
- Serious primary diseases of the cardiovascular, nervous, respiratory,hepatobiliary immunology，and endocrine systems;
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2025
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05965063
Start Date
September 1 2023
End Date
March 31 2025
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 021